212 related articles for article (PubMed ID: 21097671)
1. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.
Sloand EM; Melenhorst JJ; Tucker ZC; Pfannes L; Brenchley JM; Yong A; Visconte V; Wu C; Gostick E; Scheinberg P; Olnes MJ; Douek DC; Price DA; Barrett AJ; Young NS
Blood; 2011 Mar; 117(9):2691-9. PubMed ID: 21097671
[TBL] [Abstract][Full Text] [Related]
2. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
Sloand EM; Mainwaring L; Fuhrer M; Ramkissoon S; Risitano AM; Keyvanafar K; Lu J; Basu A; Barrett AJ; Young NS
Blood; 2005 Aug; 106(3):841-51. PubMed ID: 15827127
[TBL] [Abstract][Full Text] [Related]
3. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
[TBL] [Abstract][Full Text] [Related]
4. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
6. WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.
Suwabe T; Shibasaki Y; Sato H; Tamura S; Katagiri T; Nemoto H; Kasami T; Kozakai T; Nanba A; Kitajima T; Fuse K; Ushiki T; Sone H; Narita M; Masuko M
Int J Hematol; 2021 May; 113(5):723-734. PubMed ID: 33502734
[TBL] [Abstract][Full Text] [Related]
7. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
[TBL] [Abstract][Full Text] [Related]
9. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow.
Van Dijk JP; Knops GH; Van De Locht LT; Menke AL; Jansen JH; Mensink EJ; Raymakers RA; De Witte T
Br J Haematol; 2002 Sep; 118(4):1027-33. PubMed ID: 12199781
[TBL] [Abstract][Full Text] [Related]
10. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
11. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.
Falkenburg WJ; Melenhorst JJ; van de Meent M; Kester MG; Hombrink P; Heemskerk MH; Hagedoorn RS; Gostick E; Price DA; Falkenburg JH; Barrett AJ; Jedema I
J Immunol; 2011 Sep; 187(5):2824-33. PubMed ID: 21821799
[TBL] [Abstract][Full Text] [Related]
13. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
14. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
Rezvani K; Yong AS; Savani BN; Mielke S; Keyvanfar K; Gostick E; Price DA; Douek DC; Barrett AJ
Blood; 2007 Sep; 110(6):1924-32. PubMed ID: 17505014
[TBL] [Abstract][Full Text] [Related]
16. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Tawara I; Kageyama S; Miyahara Y; Fujiwara H; Nishida T; Akatsuka Y; Ikeda H; Tanimoto K; Terakura S; Murata M; Inaguma Y; Masuya M; Inoue N; Kidokoro T; Okamoto S; Tomura D; Chono H; Nukaya I; Mineno J; Naoe T; Emi N; Yasukawa M; Katayama N; Shiku H
Blood; 2017 Nov; 130(18):1985-1994. PubMed ID: 28860210
[TBL] [Abstract][Full Text] [Related]
17. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
[TBL] [Abstract][Full Text] [Related]
20. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
